Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HRH1 | P35367 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mezepine SCHEMBL38660320 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| SCHEMBL7843815 | 0.80 | ALDH1A1 (0.41) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| SCHEMBL25699276 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| Prazepine SCHEMBL2109939 | 0.79 | HRH1 (0.55) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| SCHEMBL20476301 | 0.75 | CYP1A2 (0.58) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| SCHEMBL11476563 | 0.74 | SLC6A2 (0.50) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| Desipramine SCHEMBL29379525 | 0.71 | SLC6A4 (1.00) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| Desipramine SCHEMBL34384 | 0.71 | SLC6A4 (1.00) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| Desipramine SCHEMBL5072939 | 0.71 | SLC6A4 (1.00) | SLC6A2SLC6A4HTR2AHRH1CYP3A4 | |
| SCHEMBL11993891 | 0.71 | NAMPT (0.56) | CYP3A4CYP1A2CYP2D6DRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | claimed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | claimed |
| CN-117597126-A | Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant | 国立癌症中心 | 2024-02-23 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2013126205-A1 | MIXED MONOAMINE REUPTAKE INHIBITOR IN A BIODEGRADABLE POLYMER CARRIER | WARSAW ORTHOPEDIC, INC. (US) | 2013-08-29 | — | — | WO | claimed |
| US-20130217673-A1 | MIXED MONOAMINE REUPTAKE INHIBITOR IN A BIODEGRADABLE POLYMER CARRIER | WARSAW ORTHOPEDIC, INC (US) | 2013-08-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | disclosed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | disclosed |
| CN-117597126-A | Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant | 国立癌症中心 | 2024-02-23 | — | — | CN | disclosed |
| CN-117241786-A | Method for preparing dry powder by using film freezing based on suspension | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | SLC6A2 2713/4885SLC6A4 2995/4885HTR2A 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.